NCT06476301View on ClinicalTrials.gov

Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

250

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

December 31, 2026

Conditions

Anticoagulation

Interventions

DRUG

Rivaroxaban

To compare the efficacy and safety of rivaroxaban as an early anticoagulant therapy for BPV patients with the traditional postoperative anticoagulant warfarin

All Listed Sponsors

lead

RenJi Hospital

OTHER

NCT06476301 - Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves | Biotech Hunter | Biotech Hunter